News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
104,440 Results
Type
Article (8353)
Company Profile (39)
Press Release (96048)
Section
Business (30472)
Career Advice (190)
Deals (4545)
Drug Delivery (42)
Drug Development (15782)
Employer Resources (22)
FDA (3275)
Job Trends (2383)
News (54606)
Policy (6772)
Tag
2024 BioForest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
2026 Pharm Country Premier (1)
Academia (525)
Accelerated approval (2)
Adcomms (8)
Allergies (32)
Alliances (9677)
ALS (21)
Alzheimer's disease (318)
Antibody-drug conjugate (ADC) (45)
Approvals (3267)
Artificial intelligence (40)
Autoimmune disease (8)
Automation (3)
Bankruptcy (27)
Best Places to Work (2007)
BIOSECURE Act (18)
Biosimilars (74)
Biotechnology (26)
Bladder cancer (21)
Brain cancer (7)
Breast cancer (57)
Cancer (460)
Cardiovascular disease (33)
Career advice (165)
Career pathing (4)
CAR-T (27)
Cell therapy (94)
Cervical cancer (3)
Clinical research (12656)
Collaboration (188)
Compensation (40)
Complete response letters (10)
COVID-19 (668)
CRISPR (8)
C-suite (53)
Cystic fibrosis (20)
Data (427)
Denatured (2)
Depression (14)
Diabetes (40)
Diagnostics (645)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (9)
Drug discovery (26)
Drug pricing (30)
Drug shortages (2)
Duchenne muscular dystrophy (35)
Earnings (10316)
Editorial (14)
Employer branding (3)
Employer resources (20)
Events (13445)
Executive appointments (124)
FDA (3615)
Featured Employer (9)
Frontotemporal dementia (1)
Funding (155)
Gene editing (27)
Generative AI (6)
Gene therapy (91)
GLP-1 (163)
Government (1440)
Grass and pollen (2)
Guidances (11)
Healthcare (2297)
Huntington's disease (7)
IgA nephropathy (3)
Immunology and inflammation (40)
Indications (8)
Infectious disease (702)
Inflammatory bowel disease (48)
Inflation Reduction Act (5)
Influenza (15)
Intellectual property (11)
Interviews (24)
IPO (2028)
IRA (18)
Job creations (453)
Job search strategy (151)
Kidney cancer (2)
Labor market (6)
Layoffs (83)
Legal (772)
Liver cancer (16)
Lung cancer (76)
Lymphoma (27)
Machine learning (1)
Management (5)
Manufacturing (102)
MASH (17)
Medical device (1553)
Medtech (1554)
Mergers & acquisitions (2611)
Metabolic disorders (124)
Multiple sclerosis (15)
NASH (4)
Neurodegenerative disease (27)
Neuropsychiatric disorders (6)
Neuroscience (425)
NextGen: Class of 2025 (887)
Non-profit (456)
Northern California (478)
Now hiring (12)
Obesity (56)
Opinion (61)
Ovarian cancer (20)
Pain (13)
Pancreatic cancer (14)
Parkinson's disease (14)
Partnered (3)
Patents (34)
Patient recruitment (19)
Peanut (21)
People (8848)
Pharmaceutical (11)
Pharmacy benefit managers (4)
Phase I (4158)
Phase II (5272)
Phase III (4647)
Pipeline (281)
Podcasts (57)
Policy (60)
Postmarket research (365)
Preclinical (1617)
Press Release (66)
Prostate cancer (16)
Psychedelics (19)
Radiopharmaceuticals (39)
Rare diseases (85)
Real estate (1041)
Recruiting (7)
Regulatory (5234)
Reports (12)
Research institute (470)
Resumes & cover letters (22)
RNA editing (1)
RSV (10)
Schizophrenia (25)
Series A (38)
Series B (14)
Service/supplier (3)
Sickle cell disease (9)
Southern California (471)
Special edition (10)
Spinal muscular atrophy (24)
Sponsored (9)
Startups (648)
State (1)
Stomach cancer (4)
Supply chain (10)
The Weekly (53)
United States (4238)
Vaccines (221)
Venture capitalists (4)
Webinars (1)
Weight loss (40)
Women's health (3)
Worklife (1)
Date
Today (53)
Last 7 days (188)
Last 30 days (608)
Last 365 days (6959)
2025 (1750)
2024 (7112)
2023 (7565)
2022 (9886)
2021 (10491)
2020 (9132)
2019 (6869)
2018 (5382)
2017 (5694)
2016 (5202)
2015 (6079)
2014 (4200)
2013 (3333)
2012 (3492)
2011 (3654)
2010 (2902)
Location
Africa (114)
Alabama (11)
Alaska (1)
Arizona (20)
Arkansas (2)
Asia (7905)
Australia (972)
California (1128)
Canada (251)
China (175)
Colorado (33)
Connecticut (27)
Delaware (36)
Europe (15165)
Florida (143)
Georgia (20)
Idaho (14)
Illinois (59)
India (11)
Indiana (79)
Iowa (1)
Japan (27)
Kansas (5)
Kentucky (10)
Louisiana (2)
Maine (5)
Maryland (316)
Massachusetts (795)
Michigan (43)
Minnesota (46)
Mississippi (1)
Missouri (14)
Montana (5)
Nebraska (1)
Nevada (4)
New Hampshire (3)
New Jersey (454)
New Mexico (5)
New York (342)
North Carolina (204)
North Dakota (7)
Northern California (478)
Ohio (42)
Oklahoma (7)
Oregon (3)
Pennsylvania (189)
Puerto Rico (1)
Rhode Island (6)
South America (161)
South Carolina (2)
Southern California (471)
Tennessee (8)
Texas (145)
Utah (24)
Virginia (15)
Washington D.C. (6)
Washington State (87)
West Virginia (1)
Wisconsin (8)
104,440 Results for "heat biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren
Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide catch up?
March 17, 2025
·
3 min read
·
Jia Jie Chen
Job Trends
Hiring Outlook: Job Market Yet to Heat Up, But Layoffs Cool Off
While hiring activity has not yet picked up, it should do so soon, according to
BioSpace
Recruitment Manager Greg Clouse. Meanwhile, another year-over-year decrease in layoffs means less competition for jobs.
March 6, 2025
·
3 min read
·
Angela Gabriel
Earnings
Merck’s Gardasil Woes Grow as China Trade War Heats Up
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
February 4, 2025
·
4 min read
·
Annalee Armstrong
Policy
ColdVentures Unveils First-of-its-Kind, Class 1 FDA Medical Device ColdVest to Prevent Heat-Related Deaths
With annual heat-related deaths projected to increase 370 percent by 2050, rising temperatures and extreme heat events pose a significant threat to humans.
June 18, 2024
·
2 min read
Weight loss
FDA Proposes Draft Guidance for Weight-Loss Therapies as Obesity Space Heats Up
The FDA recommended maintaining a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of their investigational obesity candidates.
January 8, 2025
·
2 min read
·
Tristan Manalac
MASH
Novo, Viking Heat Up MASH Space with Promising Data at AASLD24
Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging backbone of MASH treatment, with the potential to combine it with other drug classes to achieve deeper responses, according to BMO Capital Markets analyst Evan Seigerman.
November 20, 2024
·
3 min read
·
Tristan Manalac
Podcast
RFK Jr. Advances, Q4 Earnings Roll Out and a Non-Opioid Pain Drug Hits the Market
Robert F. Kennedy Jr.’s HHS nomination moves to a full Senate vote; Donald Trump’s tariff war sparks China-related concerns for biopharma; Pfizer, Merck and more announce Q4 and 2024 earnings; and the non-opioid painkiller space heats up as FDA approves Vertex’s Jounavx.
February 5, 2025
·
1 min read
·
Heather McKenzie
IPO
Metsera Seeks $289M Raise, $1.78B Valuation in IPO
The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.
January 27, 2025
·
1 min read
·
Dan Samorodnitsky
Government
At Confirmation Hearing, RFK Jr. Downplays Anti-Vax Concerns
Kennedy’s confirmation hearing on Wednesday became heated as Democratic senators grilled the nominee for HHS Secretary on his previous statements about vaccine safety.
January 30, 2025
·
2 min read
·
Tristan Manalac
IgA nephropathy
Biogen, Vertex Heat Up IgAN Arena With Mid-Stage Readouts at ASN 2024
William Blair analyst Myles Minter in a Monday note to investors said that Vertex’s povetacicept “has maintained its potential to be a best-in-class asset” in the IgA nephropathy space and could become a “multibillion-dollar pipeline-in-a-drug product” for autoimmune disorders, while “outstanding questions” remain for Biogen’s felzartamab before moving into pivotal studies.
October 28, 2024
·
3 min read
·
Tristan Manalac
1 of 10,444
Next